ASAne J. Schei-Andersen

Ane J. Schei-Andersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ane J. Schei-Andersen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep Phenotyping of Pathology‐Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients

    by Ane J. Schei‐Andersen, Janneke H. M. Schuurs‐Hoeijmakers, Rachel van der Post, Arjen R. Mensenkamp, Jolanda Schieving, PTEN Study Group, Janet R. Vos, Nicoline Hoogerbrugge

    PTEN Hamartoma Tumor Syndrome (PHTS) is a rare hereditary syndrome. PHTS has a variable phenotype characterized by benign lesions and increased cancer risks. Clarifying the extent of the benign phenotype could facilitate early recognition of PHTS patients before cancer development. Therefore, we assessed the spectrum, frequency, and age of excerpt of pathology‐confirmed benign lesions in PHTS patients. Pathology reports were collected for 379 patients with a pathogenic PTEN variant from the Dutch nationwide pathology databank (Palga). Benign lesions were classified as PHTS‐related based on current clinical diagnostic guidelines and non‐PHTS‐related lesions by ICD‐10 codes. Age of last follow‐up was year of pathology request minus birth year. Analyses were stratified by sex and index status. Patients presented mainly with gastrointestinal (54%), skin (47%), thyroid (31%) and vascular lesions (26%). Males developed lipomas at an early age (9 years (5–34)). Females developed endometrial hyperplasia (16%) at an earlier age (41 years (35–49)) and uterine polyps (13%) more often than the general population. No significant differences were observed between sexes or index and non‐index patients. The results are reflective of current diagnostic guidelines. Early‐onset lipomas may be useful for early detection of PHTS patients. Additionally, uterine polyps should be considered for inclusion as a PHTS‐related lesion.


  • Open Access

    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single‐center study

    by Ane J. Schei‐Andersen, Linda A. J. Hendricks, Rachel S. van der Post, Arjen R. Mensenkamp, Jolanda Schieving, PTEN Study Group, Janneke H. M. Schuurs‐Hoeijmakers, Nicoline Hoogerbrugge, Janet R. Vos

    PTEN hamartoma tumor syndrome (PHTS) has a broad clinical spectrum including various benign and malignant tumors at varying age of diagnosis. Many patients remain unrecognized, unaware of their increased cancer risk. We aimed to describe the cancer spectrum, age of onset and histopathological cancer characteristics to assess whether specific cancer characteristics could improve PHTS recognition. Genetic testing results and pathology reports were collected for patients tested for germline PTEN variants between 1997 and 2020 from the diagnostic laboratory and the Dutch nationwide pathology databank (Palga). The cancer spectrum and age of onset were assessed in patients with (PTENpos) and without (PTENneg) a germline PTEN variant. Histopathological cancer characteristics were assessed in a nested cohort. 341 PTENpos patients (56% females) and 2882 PTENneg patients (66% females) were included. PTENpos patients presented mostly with female breast (BC, 30%), endometrial (EC, 6%), thyroid (TC, 4%) or colorectal cancer (4%). PTENpos were significantly younger at cancer onset (43 vs. 47 years) and had more often (46% vs. 18%) a second BC than PTENneg. PTEN detection rates were highest for BC <40 years (9%), TC <20 years (15%) and EC <50 years (28%), and dropped to 6%, 4%, and 15% by age 60. Histopathological characteristics were similar between groups. No histopathological cancer characteristics were distinctive for PHTS. However, PTENpos were significantly younger at cancer onset. Therefore early‐onset BC, EC, or TC warrants consideration of PHTS diagnostics either through a pre‐screen for other PHTS features or direct germline testing.


  • Open Access

    Exploring the Prevalence of Oral Features for Early Detection of PTEN Hamartoma Tumour Syndrome

    by Ane J. Schei-Andersen, Bart van Oirschot, Meggie M.C.M. Drissen, Jolanda Schieving, Janneke H.M. Schuurs-Hoeijmakers, Janet R. Vos, Claire M. Barton, Nicoline Hoogerbrugge